Concepedia

Matthew A. Belmonte

MA

Statistics

Publications

8

Citations

891

H-Index

8

Active since

2013

Affiliations

AstraZeneca (United Kingdom)(Current)

AstraZeneca (United States)

Matthew A. Belmonte is an author at AstraZeneca (United Kingdom) specializing in pharmacology, medicine, and drug discovery.

Publications per year

2013–2019

8

Publications

8

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

Adriana E. Tron, Matthew A. Belmonte, Ammar Adam et al. · Nature Communications · 2018 · 486 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain

Gizem Akçay, Matthew A. Belmonte, Brian Aquila et al. · Nature Chemical Biology · 2016 · 194 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors

Jeffrey W. Johannes, Stephanie M. Bates, Carl Beigie et al. · ACS Medicinal Chemistry Letters · 2016 · 60 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Development of Frataxin Gene Expression Measures for the Evaluation of Experimental Treatments in Friedreich’s Ataxia

Heather L. Plasterer, Éric Deutsch, Matthew A. Belmonte et al. · PLoS ONE · 2013 · 44 citations · Full text

Medicine, Neurology, Pharmacology +16

The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells

Shaheen Kabir, Justin Cidado, Courtney L. Andersen et al. · eLife · 2019 · 43 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

1–5 of 8